Cancer Quality Measures
Cedars-Sinai Cancer aims to deliver the highest-quality care to all our cancer patients. We constantly strive to follow the latest evidence-based guidelines that will result in the best outcomes for our patients. The patient-satisfaction scores listed below show that a significant percentage of our patients would highly recommend our care providers when asked to rank the providers using a scale from 0 to 5, where 0 is the worst/least likely to recommend care provider and 5 is the best/most likely to recommend care provider. The number below represents the percentage of patients who selected the most positive response choice for their care provider.
Patient Satisfaction (July 1, 2022—May 1, 2023)Likelihood to Recommend Care Provider |
|
---|---|
Samuel Oschin Cancer Center |
94.6% |
Saul and Joyce Brandman Breast Center—A Project of Women’s Guild |
91.4% |
Radiation Oncology |
95.2% |
Source: Press Ganey
To demonstrate our commitment to quality care, Cedars-Sinai Cancer at Cedars-Sinai Medical Center is accredited by the Commission on Cancer and participates in monitoring care associated with the quality-of-care guidelines for cancer care endorsed by the Commission on Cancer, the National Quality Forum, the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
These quality-of-care guidelines include:
Breast
- Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer.
- First therapeutic breast surgery in a non-neoadjuvant setting is performed within 60 days of diagnosis for patients with American Joint Committee on Cancer (AJCC) clinical stage 1-3 breast cancer.
Colorectal
- At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
Gastric
- At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer.
Lung
- Systemic chemotherapy is administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) non-small cell lung cancer.
Melanoma
- Melanoma adjuvant systemic therapy was administered within six months of surgery or recommended for eligible patients with stage 3B-3D resected melanoma.
For diagnostic year 2022, Cedars-Sinai’s performance with evidence-based guidelines for cancer care for select cancers/tumor sites is presented below. (Data provided by the National Cancer Database.)
Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conservation surgery for breast cancer. |
Percentage for diagnostic year 2022 |
---|---|
Cedars-Sinai |
92.17% |
State of California |
73.51% |
Pacific region |
78.46% |
Teaching hospitals |
82.09% |
All Commission on Cancer-approved programs |
82.11% |
First therapeutic breast surgery in a non-neoadjuvant setting is performed within 60 days of diagnosis for patients with AJCC clinical stage 1-3 breast cancer. |
Percentage for diagnostic year 2022 |
---|---|
Cedars-Sinai |
82.39% |
State of California |
64.05% |
Pacific region |
69.01% |
Teaching hospitals |
68.69% |
All Commission on Cancer-approved programs |
75.33% |
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. |
Percentage for diagnostic year 2022 |
---|---|
Cedars-Sinai |
100% |
State of California |
94.73% |
Pacific region |
95.36% |
Teaching hospitals |
96.64% |
All Commission on Cancer-approved programs |
95.08% |
At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer. |
Percentage for diagnostic year 2022 |
---|---|
Cedars-Sinai |
100% |
State of California |
76.3% |
Pacific region |
78.85% |
Teaching hospitals |
77.9% |
All Commission on Cancer-approved programs |
73.59% |
Systemic chemotherapy is administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is recommended for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) non-small cell lung cancer. |
Percentage for diagnostic year 2022 |
---|---|
Cedars-Sinai |
90% |
State of California |
80.02% |
Pacific region |
86.53% |
Teaching hospitals |
88.64% |
All Commission on Cancer-approved programs |
90.01% |
Melanoma adjuvant systemic therapy was administered within six months of surgery or recommended for eligible patients with stage 3B-3D resected melanoma. |
Percentage for diagnostic year 2022 |
---|---|
Cedars-Sinai |
100% |
State of California |
76.25% |
Pacific region |
80% |
Teaching hospitals |
81.86% |
All Commission on Cancer-approved programs |
82.66% |
Have Questions or Need Help?
If you have questions or wish to learn more about quality measures at Cedars-Sinai, please send us a message.